查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1853763

癌症恶病质市场按治疗类型、通路、给药途径、最终用户和患者人口统计特征划分－2025-2032年全球预测

Cancer Cachexia Market by Treatment Type, Distribution Channel, Route Of Administration, End User, Patient Demographics - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，癌症恶病质市场规模将成长 41 亿美元，复合年增长率为 7.82%。

关键市场统计数据
基准年2024年 22.4亿美元
预计年份：2025年 24.2亿美元
预测年份 2032 41亿美元
复合年增长率 (%) 7.82%

为癌症恶病质建构了一个简洁权威的框架，重点阐述了其临床复杂性、不断发展的科学进展以及整合治疗和护理策略的必要性。

癌症恶病质仍然是一种复杂的、多因素综合征，它会损害患者康復，使癌症治疗更加复杂，并给商业性和临床相关人员带来挑战。早期识别恶病质、整合多学科管理以及使治疗策略与以患者为中心的结果一致，是常见的临床要务。最新的临床实践指南强调了营养支持、药物干预和针对症状的治疗的必要性。

同时，病理学研究揭示了包括全身性发炎、代谢异常和神经激素讯号传导在内的多种机制。这些进展重新激发了人们对开发能够调节食慾、抑制分解代谢并干预与肌肉流失相关的信号通路药物的兴趣。因此，从医疗器材製造商到营养补充剂开发商再到製药公司，相关人员在重新评估自身在需要跨医疗环境和交付模式的综合解决方案的生态系统中的角色。

因此，本导言为理解不断发展的科学、不断变化的医疗服务模式以及新的商业性需求如何相互作用，从而塑造机会和风险奠定了基础。在此背景下，接下来的章节将探讨不断变化的市场格局、价格动态变化的影响、可操作的市场区隔和区域洞察，并为希望将洞察说明为实际影响的产业领导者提供明确的建议。

新的科学突破、重新设计的诊疗路径以及数位化医疗服务正在融合，重新定义恶病质治疗的研发和商业模式。

由于科学、临床和商业性力量的汇聚，癌症恶病质的治疗格局正在改变性变化。基础科学的进展加深了我们对发炎介质、代谢重编程和食慾调节路径的理解，从而推动了标靶药物的研发，并重新激发了人们对合成代谢和食慾刺激药物的兴趣。同时，临床医生正在采用更早期的筛检和评估框架，将临床路径从被动的危机管理转向主动的支持性治疗，从而催生了对能够在早期干预窗口期内使用的产品和服务的需求。

同时，技术赋能的照护模式和远端医疗正在加速发展，使得在传统门诊就诊之外，能够更频繁地监测体重、功能状态和营养摄取量。这些模式有助于收集长期数据并提高患者参与度，从而提升结合药物治疗、营养治疗和物理復健的多模式介入措施的可行性。此外，监管机构和支付者越来越认可能够证明功能获益和病患报告结果的证据，这提高了临床研发的标准，同时也为那些能够显着改善生活品质的治疗方法开闢了新的报销途径。

商业动态也在改变。随着患者和看护者寻求便捷的网路基地台辅助护理产品和补充剂，製造商和服务供应商必须适应通路多元化。同时，製药公司、营养品公司和医疗器材製造商之间正在建立策略伙伴关係，以提供兼顾生物学因素和辅助需求的综合解决方案。这种变革性的转变不仅限于科学和医疗服务，而是遍及整个价值链，需要整合临床证据、分销能力和支付方参与度的整合策略。

2025年关税政策的变化正在再形成采购、製造策略和支付方监管，从而改变恶病质相关疗法和耗材的商业规划。

2025年新关税政策的实施，将进一步增加癌症恶病质相关治疗药物、医疗设备和营养产品的供应链和采购计画的复杂性。跨境贸易成本的增加引发了人们对筹资策略、定价以及分销网络韧性的担忧。采购团队和商业领导者必须权衡投入成本的短期影响与长期决策之间的关係，例如在地化生产、重新谈判合约以及在保障净利率的同时维持病患用药可及性的库存策略。

因此，企业正在考虑采用近岸外包和双重采购策略来降低关税波动带来的风险，同时也重新评估与经销商和批发商的合约条款，以便更公平地分配供应链风险。此外，这些变化将影响市场推广策略，价格敏感型管道可能需要不同的促销策略和支援模式来维持销售。对于依赖低温运输和特殊包装的治疗药物而言，关税负担的加重将增加现有营运的复杂性，促使企业投资于流程效率和供应链透明度。

最后，相关人员应预料到关税带来的成本压力将加速对经济价值和实际效果证据的需求。不断上涨的采购成本将迫使医疗支付者和医疗系统更加严格地审查有关功能改进和资源消耗降低的说法。因此，那些积极调整采购、生产和价值论证策略的组织，将更有能力在不断变化的贸易动态环境中保持市场准入和商业性发展势头。

多维细分框架将治疗方式、分销管道、给药途径、治疗环境和患者人口统计特征结合起来，为制定个人化策略提供依据。

细緻的细分观点揭示了临床需求与给药方式和商业机会的交会点。根据治疗类型，相关人员应考虑医疗设备医疗设备和膳食补充剂通常依赖功能获益和依从性的实际验证，而药品则通常需要进行对照试验来确定其疗效和安全性。

分销管道细分揭示了获取途径如何影响药物的接受度和患者体验，医院、线上药房和零售药房各自提供不同的用药支援、咨询和追踪服务。通路选择会影响处方笺发放、处方医生的认知以及患者支持计画的设计。给药途径细分阐明了注射剂和口服药物在临床和操作方面的权衡，并将注射剂进一步细分为静脉注射和皮下注射。注射剂可能需要医疗机构资源和低温运输物流，而口服药物通常优先考虑门诊和居家照护中的用药依从性支持和便利性。

将终端使用者细分为门诊、居家医疗和医院三大类，凸显了介入措施必须与护理团队和工作流程整合的环节。居家照护环境越来越需要简化的治疗方案和强大的远端监测功能，而医院介入措施则可以利用多学科团队和强化支援服务。成人、老年人和儿童群体具有独特的生理反应和护理考量，男女患者的差异也会影响症状表现、剂量选择和支持需求。总而言之，这些细分群体构成了一个多维格局，产品设计、临床证据产生和商业性策略必须满足每个治疗管道、途径、使用者和患者的特定需求。

美洲、欧洲、中东和非洲以及亚太地区的区域性考量将推动恶病质治疗取得、实证医学证据产生和供应链韧性策略的协调一致。

区域动态对临床实践、报销途径和供应链设计有显着影响，因此领导者需要将区域模式转化为可执行的计划。在美洲，医疗保健系统呈现多样化的支付模式，并高度重视真实世界证据和结果，以此作为报销决策的依据。在这种环境下，那些拥有可证实的功能效益和经济价值分析支持，且能引起整合医疗服务网络和私人支付方共鸣的产品更受青睐。

欧洲、中东和非洲地区法律规范和支付体系的碎片化，使得打入市场策略必须灵活调整，而本地证据的收集和相关人员的参与在市场进入过程中发挥着至关重要的作用。在欧洲部分地区，价格压力和预算限制促使企业更加关注成本效益和患者获益；而在中东和非洲部分地区，则存在着透过伙伴关係主导的主导开发和能力伙伴关係来支持治疗服务的机会。在整个全部区域范围内，协调通路伙伴关係、本地生产和采购策略可以提高应对力和可负担性。

亚太地区多元化的经济状况和快速发展的医疗保健投资正在重塑对综合性恶病质解决方案的需求。该地区部分市场优先采用数位化医疗和居家照护模式，以实现可扩展的远端监测和患者援助计画。而在其他地区，由于医疗资源分散且报销途径多样，需要开展重点试点计画并进行强有力的临床倡导，以证明其价值。在所有地区，监管策略、供应链韧性和文化敏感性病人参与的策略性协调将决定哪些产品能够获得持续的认可。

製药、营养品、医疗设备、生物技术和服务供应商之间的竞争与合作动态揭示了通往整合解决方案和伙伴关係主导规模化的路径。

竞争格局反映了成熟製药企业、专业医疗器材製造商、营养品公司和新兴生技公司等各方力量的融合，它们各自为恶病质生态系统带来独特的优势。製药公司致力于研发标靶分子，旨在刺激食慾、促进合成代谢和调节发炎反应，并常常在进行对照试验和与监管机构沟通方面发挥主导。营养品相关企业和膳食补充剂供应商则透过专注于热量和蛋白质输送、微量营养素优化以及提高患者依从性的技术，为药物治疗提供补充，从而改善整体治疗效果。

医疗器材製造商正在提供给药平台、监测工具和配套技术，以促进对给药和功能终点的长期评估。新兴生物技术公司和临床阶段的研发企业也在引入创新方法来扩展治疗套件，并可能与大型公司合作，以扩大研发和商业化规模。这些相关人员之间的策略联盟十分常见，因为联合产品可以解决恶病质的多种驱动因素​​，并为临床医生、相关人员和患者提供更具吸引力的提案主张。

最后，专注于居家输液、营养咨询和远端监测的服务供应商在推广应用方面发挥着至关重要的作用，他们能够减少使用障碍并提高患者依从性。这些服务提供者通常是重要的分销和支援合作伙伴，能够扩大服务覆盖范围并产生真实世界证据以支持临床价值主张。对于正在评估竞争对手和潜在合作伙伴的机构而言，能够展现出在证据生成、物流配送和以患者为中心的支持等方面综合能力的合作伙伴更具优势。

领导者可采取切实可行的策略重点，协调临床证据、供应链韧性、数位化赋能和跨部门伙伴关係，以加速产生影响力。

产业领导者应进行有针对性的投资，使科学前景与实际应用模式相契合，同时积极降低商业性和营运风险。首先，应优先考虑儘早识别并利用标准化筛检方案和远端监测工具纳入患者群体，以便儘早展现临床效益并优化治疗路径。同时，应设计包含功能性结果和患者报告结果的临床项目，并在传统终点指标的基础上，纳入这些指标，以满足支付方的期望并支持报销谈判。

第二，我们将建构灵活的供应链策略，包括替代采购管道、在适当情况下采用近岸外包，并与通路伙伴携手合作，在关税和物流压力下维持供应。同时，我们将建立伙伴关係，整合药品、营养品和医疗设备的能力，简化临床医师和支付者的决策流程。第三，我们将投资于数位健康和​​患者援助平台，以提高患者依从性、收集真实世界疗效数据并实现基于价值的合约。这些投资也将有助于提高病人参与和改善长期疗效。

最后，他们采用在地化的市场推广策略，根据当地支付方的要求和医疗模式调整证据产生、定价和销售策略。整合这些方法——临床相关性、供应链韧性、跨部门伙伴关係、数位化和在地化客製化——使机构能够将科学进步转化为永续的患者获益和商业性成功。

一项严谨的混合方法研究途径，结合文献综述、相关人员访谈、案例研究和情境分析，为得出可操作的见解提供了支持。

为了全面了解恶病质生态系统，本研究整合了同行评审的临床文献、监管倡议、真实世界证据计画以及与临床医生、相关人员和供应链专家的访谈。资料收集着重于多资讯来源三角验证，以检验趋势并确保资料既反映临床实际情况又兼顾商业性限制。定性资料辅以产品上市、分销模式和证据产生策略的案例研究，旨在揭示市场准入和规模化发展的实用经验。

分析方法包括对科学进展进行主题综合分析、对供应链和关税影响进行情境分析，以及透过细分映射来协调治疗方法和管道、途径、医疗机构和患者群体。相关人员访谈探讨了临床应用的驱动因素、报销预期和营运障碍，而二手文献则提供了关于疾病机制和治疗方法演变的背景资讯。在整个过程中，我们始终强调资讯来源类型的透明度，并明确区分已建立的证据和新兴的假设，以指导实际决策。

简洁扼要的结论强调了整合证据、交付模式和伙伴关係以产生持久影响的临床紧迫性和策略必要性。

癌症恶病质既是沉重的临床负担，也是创新、综合解决方案的良机，这些方案融合了药物、营养、器械和服务等要素。科学进步、变革性医疗服务和商业性模式的融合，为相关人员重新思考以功能性结果和病患体验为优先的治疗策略提供了机会。同时，政策变化和价格动态也要求制定周密的营运计划，以确保患者能够获得治疗并实现永续的商业化。

总之，成功应对恶病质取决于各机构能否将严谨的证据生成与灵活的服务模式结合，能否跨领域建立策略合作，以及能否透过充分展现功能性和经济价值来赢得支付方的信任。那些能够有效整合临床、商业和营运策略的公司，将能够为患者带来可衡量的益处，并为投资者和合作伙伴创造可持续的利润。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 整合多模式营养支持和运动通讯协定以改善患者预后
  • Ghrelin肽受体促效剂疗法的进展已显示出改善体重增加的效果
  • 用于早期检测和进展监测的新兴生物标记
  • 远端医疗平台在远距监测恶病质治疗依从性方面的应用日益广泛
  • 开发针对代谢途径的联合药物疗法以减少肌肉萎缩
  • 增加对个人化医疗方法的投资，以便根据患者表型客製化恶病质干预措施
  • 整合机器学习演算法以预测恶病质的发生并优化治疗策略
  • 越来越重视患者报告结局，以评估恶病质试验中的生活品质改善情况

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 依治疗类型分類的癌症恶病质市场

  • 医疗设备
  • 营养补充品和膳食补充剂
  • 製药
    • 阿拉莫林
    • 刺激食慾
    • 皮质类固醇

9. 按分销管道分類的癌症恶病质市场

  • 医院药房
  • 网路药房
  • 零售药局

第十章 依给药途径分類的癌症恶病质市场

  • 注射
    • 静脉
    • 皮下
  • 口服

第十一章 以最终用户分類的癌症恶病质市场

  • 门诊治疗
  • 居家照护
  • 医院

12. 依患者人口统计特征分類的癌症恶病质市场

  • 年龄组
    • 成人
    • 老年人
    • 孩子们
  • 性别
    • 女士
    • 男性

第十三章 各地区的癌症恶病质市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 癌症恶病质市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国癌症恶病质市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Helsinn Holding SA
    • Qilu Pharmaceutical Co., Ltd.
    • Merck & Co., Inc.
    • Pfizer Inc.
    • Novartis AG
    • Ipsen SA
    • Bristol-Myers Squibb Company
    • Amgen Inc.
    • Astellas Pharma Inc.
    • Johnson & Johnson
Product Code: MRR-02026C4C92B4

The Cancer Cachexia Market is projected to grow by USD 4.10 billion at a CAGR of 7.82% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 2.24 billion
Estimated Year [2025] USD 2.42 billion
Forecast Year [2032] USD 4.10 billion
CAGR (%) 7.82%

A concise and authoritative framing of cancer cachexia that clarifies clinical complexity, evolving science, and the need for integrated therapeutic and care delivery strategies

Cancer cachexia remains a complex, multifactorial syndrome that undermines patient resilience, complicates oncologic care, and challenges commercial and clinical stakeholders alike. The prevailing clinical imperative is to recognize cachexia early, integrate multidisciplinary management, and align therapeutic strategies with patient-centered outcomes. Recent clinical practice guidelines emphasize the need for coordinated nutritional support, targeted pharmacologic interventions, and symptom-directed care that collectively aim to preserve function and quality of life.

At the same time, research into pathophysiology has clarified contributing mechanisms, including systemic inflammation, metabolic dysregulation, and neurohormonal signaling. These advances have driven renewed interest in developing agents that modulate appetite, counteract catabolism, or intervene in signaling pathways associated with muscle wasting. Consequently, stakeholders from device makers to supplement developers and pharmaceutical sponsors are re-evaluating their roles in an ecosystem that demands integrated solutions across care settings and delivery models.

Therefore, the introduction here sets the stage for understanding how evolving science, shifting care delivery practices, and new commercial imperatives intersect to shape opportunities and risks. With that context, subsequent sections explore transformative landscape shifts, the implications of changing tariff dynamics, actionable segmentation and regional insights, and clear recommendations for industry leaders seeking to move from insight to impact.

Emerging scientific breakthroughs, care pathway redesigns, and digital care delivery are converging to redefine therapeutic development and commercial models for cachexia management

The landscape for cancer cachexia is undergoing transformative shifts driven by converging scientific, clinical, and commercial forces. Advances in basic science have expanded understanding of inflammatory mediators, metabolic reprogramming, and appetite-regulating pathways, which in turn have catalyzed targeted drug development programs and renewed interest in anabolic and appetite-stimulating agents. Concurrently, clinicians are adopting earlier screening and assessment frameworks, shifting the clinical pathway from reactive crisis management to proactive supportive care, and thereby creating demand for products and services that fit earlier intervention windows.

In parallel, technology-enabled care models and telehealth have accelerated, enabling more frequent monitoring of weight, functional capacity, and nutritional intake outside traditional clinic visits. These models facilitate longitudinal data collection and patient engagement, improving the feasibility of multidimensional interventions that combine pharmacotherapy, nutrition, and physical rehabilitation. Moreover, regulators and payers are increasingly receptive to evidence demonstrating functional benefit and patient-reported outcomes, which raises the bar for clinical development while also opening new reimbursement levers for therapies that show meaningful improvement in quality of life.

Commercial dynamics are also shifting. Manufacturers and service providers must adapt to channel diversification as patients and caregivers seek convenient access points for supportive care products and supplements. At the same time, strategic partnerships between pharmaceutical sponsors, nutritional companies, and device manufacturers are emerging to offer bundled solutions that address both biological drivers and supportive needs. Thus, the transformative shifts are not isolated to science or care delivery; they span the full value chain, demanding integrated strategies that align clinical evidence, distribution capabilities, and payer engagement.

Shifts in 2025 tariff policy are reshaping procurement, manufacturing strategies, and payer scrutiny in ways that alter commercial planning for cachexia-related therapies and supplies

The introduction of new tariff policies in 2025 has introduced additional complexity to supply chain and procurement planning for therapies, medical devices, and nutritional products relevant to cancer cachexia. Increased cross-border trade costs raise questions about sourcing strategies, pricing structures, and the resilience of distribution networks. Procurement teams and commercial leaders must weigh the immediate implications for input costs against longer-term decisions about manufacturing localization, contract renegotiations, and inventory strategies that preserve patient access while protecting margins.

Consequently, organizations are examining nearshoring and dual-sourcing approaches to mitigate exposure to tariff volatility, while also reassessing contractual terms with distributors and wholesalers to allocate risk more equitably across the supply chain. In turn, these shifts influence go-to-market tactics, as price-sensitive channels may demand different promotional strategies and support models to maintain uptake. For therapeutics that rely on cold chain logistics or specialized packaging, the incremental tariff burden compounds existing operational complexity and encourages investments in process efficiency and supply chain visibility.

Finally, stakeholders should anticipate that tariff-driven cost pressures will accelerate demand for evidence of economic value and real-world effectiveness. Payers and health systems will scrutinize claims of improved function and reduced resource utilization more closely when acquisition costs rise. Therefore, organizations that proactively adapt procurement, manufacturing, and value demonstration strategies will be better positioned to sustain access and commercial momentum in the face of changing trade policy dynamics.

A multidimensional segmentation framework that aligns treatment modalities, distribution channels, administration routes, care settings, and patient demographics to inform tailored strategies

A nuanced segmentation view reveals where clinical need intersects with delivery modalities and commercial opportunity. Based on treatment type, stakeholders must consider medical devices, nutraceuticals and supplements, and pharmaceuticals, with the pharmaceutical category subdividing into agents such as anamorelin, appetite stimulants, and corticosteroids that address distinct mechanisms and clinical objectives. This continuum requires differentiated evidence strategies: medical devices and supplements often rely on pragmatic, real-world demonstrations of functional benefit and adherence, while pharmaceuticals typically pursue controlled trials to establish efficacy and safety profiles.

Distribution channel segmentation highlights how access pathways shape adoption and patient experience, with hospital pharmacies, online pharmacies, and retail pharmacies each offering different touchpoints for dosing support, counseling, and follow-up. Channel choice influences formulary placement, visibility to prescribers, and the design of patient support programs. Route of administration segmentation underscores clinical and operational trade-offs between injectable and oral therapies, noting that injectables further divide into intravenous and subcutaneous options; injectables may demand facility resources and cold chain logistics, while oral options often emphasize adherence support and convenience for outpatient and home-based care.

End user segmentation across ambulatory care, home care, and hospitals clarifies where interventions must integrate with care teams and workflows. Home care settings increasingly require simplified regimens and robust remote monitoring, whereas hospital-based interventions can leverage multidisciplinary teams and intensive supportive services. Patient demographic segmentation by age group and gender further refines targeting, as adult, geriatric, and pediatric cohorts have unique physiological responses and care considerations, and differences between female and male patients can influence symptom presentation, dosing considerations, and support needs. Taken together, these segments create a multidimensional landscape in which product design, clinical evidence generation, and commercial tactics must align to the specific demands of each therapy-channel-route-user-patient intersection.

Regional considerations across the Americas, Europe Middle East & Africa, and Asia-Pacific drive tailored access, evidence generation, and supply chain resilience strategies for cachexia solutions

Regional dynamics materially affect clinical practice, reimbursement pathways, and supply chain design, and leaders must translate regional patterns into actionable plans. In the Americas, healthcare systems demonstrate a range of payer models and an emphasis on real-world evidence and outcomes that drive reimbursement decisions; this environment favors products backed by demonstrable functional gains and economic value analyses that resonate with integrated delivery networks and private payers. Manufacturers operating here often balance national regulatory expectations with regional differences in procurement and distribution infrastructure.

In Europe, Middle East & Africa, fragmentation across regulatory frameworks and payer systems requires adaptive market access strategies, with local evidence generation and stakeholder engagement playing a pivotal role in uptake. Pricing pressures and budget constraints in parts of Europe emphasize cost-effectiveness and patient benefit, whereas some Middle Eastern and African markets present opportunities for partnership-driven program deployment and capacity building to support therapy delivery. Across this region, tailored approaches to channel partnerships and local manufacturing or sourcing can enhance responsiveness and affordability.

In Asia-Pacific, diverse economic contexts and rapidly evolving healthcare investment are reshaping demand for integrated cachexia solutions. Some markets in the region prioritize rapid adoption of digital health and home-based care models, enabling scalable remote monitoring and patient support programs. Elsewhere, fragmented access and variable reimbursement pathways necessitate focused pilot programs and strong clinical advocacy to demonstrate value. Across all regions, strategic alignment of regulatory strategy, supply chain resilience, and culturally attuned patient engagement will determine which products gain sustainable traction.

Competitive and collaborative dynamics across pharmaceutical, nutritional, device, biotech, and service providers reveal pathways for integrated solutions and partnership-driven scale

Competitive dynamics reflect a mix of established pharmaceutical sponsors, specialty device manufacturers, nutritional companies, and emerging biotechs, each bringing distinct capabilities to the cachexia ecosystem. Pharmaceutical sponsors advance targeted molecules aimed at appetite stimulation, anabolic support, and anti-inflammatory modulation, and they often lead in controlled-evidence development and engagement with regulatory authorities. Nutritional companies and supplement providers complement pharmacologic approaches by focusing on caloric and protein delivery, micronutrient optimization, and adherence-support technologies that can enhance overall therapeutic outcomes.

Device manufacturers contribute dosing platforms, monitoring tools, and supportive technologies that facilitate administration and longitudinal assessment of functional endpoints. Emerging biotechs and clinical-stage developers are also introducing innovative modalities that expand the therapeutic toolkit and may partner with larger organizations to scale development and commercialization. Strategic alliances between these stakeholder groups are common, as combined offerings can address multiple drivers of cachexia and present a more compelling value proposition to clinicians, payers, and patients.

Finally, service providers that specialize in home infusion, nutritional counseling, and remote monitoring play a vital role in adoption by reducing barriers to use and improving adherence. These providers often function as important distribution and support partners, enabling broader access and generating real-world evidence that reinforces clinical value claims. For organizations evaluating competition and potential collaborators, the landscape favors partners who can demonstrate integrated capabilities across evidence generation, delivery logistics, and patient-centric support.

Actionable strategic priorities for leaders to align clinical evidence, supply chain resilience, digital enablement, and cross-sector partnerships to accelerate impact

Industry leaders should pursue targeted investments that align scientific promise with pragmatic delivery models while actively mitigating commercial and operational risk. First, prioritize early identification and engagement of patient cohorts through standardized screening protocols and remote monitoring tools so clinical benefit can be demonstrated earlier and care pathways can be optimized. Parallel to this, design clinical programs that incorporate functional and patient-reported outcomes alongside traditional endpoints to meet payer expectations and to support reimbursement discussions.

Second, build flexible supply chain strategies that include alternative sourcing, nearshoring where appropriate, and collaborations with channel partners to preserve access amid tariff and logistical pressures. Simultaneously, cultivate partnerships that bring together pharmaceuticals, nutrition, and device capabilities into bundled offerings to simplify decision-making for clinicians and payers. Third, invest in digital health and patient support platforms that enhance adherence, capture real-world effectiveness data, and enable value-based contracting conversations. Such investments will also improve patient engagement and long-term outcomes.

Finally, adopt a regionalized go-to-market playbook that adapts evidence generation, pricing, and distribution tactics to local payer requirements and care models. By integrating these approaches-clinical relevance, supply chain resilience, cross-sector partnerships, digital enablement, and regional tailoring-organizations can convert scientific advances into sustainable patient impact and commercial success.

A rigorous mixed-methods research approach combining literature synthesis, stakeholder interviews, case studies, and scenario analysis to support actionable insights

This research synthesizes peer-reviewed clinical literature, regulatory guidance, real-world evidence initiatives, and stakeholder interviews with clinicians, payers, and supply chain experts to develop a comprehensive view of the cachexia ecosystem. Data collection emphasized triangulation across multiple sources to validate trends and to ensure findings reflect both clinical realities and commercial constraints. Qualitative inputs were supplemented by case studies of product launches, distribution models, and evidence-generation strategies to illuminate practical lessons for market entry and scale.

Analytical methods included thematic synthesis of scientific developments, scenario analysis for supply chain and tariff impacts, and segmentation mapping to align therapeutic approaches with channels, routes, care settings, and patient cohorts. Stakeholder interviews probed clinical adoption drivers, reimbursement expectations, and operational barriers, while secondary literature provided context on evolving mechanisms of disease and therapeutic modalities. Throughout, emphasis was placed on transparency of source types and on clearly distinguishing well-established evidence from emerging hypotheses to guide pragmatic decision-making.

A succinct conclusion that underscores the clinical urgency and strategic imperative to integrate evidence, delivery models, and partnerships for durable impact

Cancer cachexia presents both a significant clinical burden and a compelling opportunity for innovative, integrated solutions that combine pharmacologic, nutritional, device, and service elements. The convergence of scientific progress, care delivery transformation, and commercial adaptation creates a window for stakeholders to reimagine therapeutic strategies that prioritize functional outcomes and patient experience. At the same time, policy shifts and tariff dynamics require careful operational planning to preserve access and enable sustainable commercialization.

In conclusion, success in addressing cachexia will rest on the ability of organizations to align rigorous evidence generation with adaptable delivery models, to form strategic collaborations across sectors, and to engage payers with robust demonstrations of functional and economic value. Those who move decisively to integrate clinical, commercial, and operational strategies will be best positioned to deliver measurable benefits to patients and durable returns for investors and partners.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of multimodal nutritional support with exercise protocols to enhance patient outcomes
  • 5.2. Advancements in ghrelin receptor agonist therapies showing improved weight gain efficacy
  • 5.3. Emergence of biomarkers for early detection and monitoring of cancer cachexia progression
  • 5.4. Rising adoption of telemedicine platforms for remote monitoring of cachexia treatment adherence
  • 5.5. Development of combination drug regimens targeting metabolic pathways to counteract muscle wasting
  • 5.6. Increasing investment in personalized medicine approaches to tailor cachexia interventions by patient phenotype
  • 5.7. Integration of machine learning algorithms to predict cachexia onset and optimize therapeutic strategies
  • 5.8. Growing focus on patient-reported outcomes to evaluate quality of life improvements in cachexia trials

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cancer Cachexia Market, by Treatment Type

  • 8.1. Medical Devices
  • 8.2. Nutraceuticals & Supplements
  • 8.3. Pharmaceutical
    • 8.3.1. Anamorelin
    • 8.3.2. Appetite Stimulants
    • 8.3.3. Corticosteroids

9. Cancer Cachexia Market, by Distribution Channel

  • 9.1. Hospital Pharmacies
  • 9.2. Online Pharmacies
  • 9.3. Retail Pharmacies

10. Cancer Cachexia Market, by Route Of Administration

  • 10.1. Injectable
    • 10.1.1. Intravenous
    • 10.1.2. Subcutaneous
  • 10.2. Oral

11. Cancer Cachexia Market, by End User

  • 11.1. Ambulatory Care
  • 11.2. Home Care
  • 11.3. Hospitals

12. Cancer Cachexia Market, by Patient Demographics

  • 12.1. Age Group
    • 12.1.1. Adult
    • 12.1.2. Geriatric
    • 12.1.3. Pediatric
  • 12.2. Gender
    • 12.2.1. Female
    • 12.2.2. Male

13. Cancer Cachexia Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Cancer Cachexia Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Cancer Cachexia Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Helsinn Holding SA
    • 16.3.2. Qilu Pharmaceutical Co., Ltd.
    • 16.3.3. Merck & Co., Inc.
    • 16.3.4. Pfizer Inc.
    • 16.3.5. Novartis AG
    • 16.3.6. Ipsen SA
    • 16.3.7. Bristol-Myers Squibb Company
    • 16.3.8. Amgen Inc.
    • 16.3.9. Astellas Pharma Inc.
    • 16.3.10. Johnson & Johnson

LIST OF FIGURES

  • FIGURE 1. GLOBAL CANCER CACHEXIA MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CANCER CACHEXIA MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL CANCER CACHEXIA MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CANCER CACHEXIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL CANCER CACHEXIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CANCER CACHEXIA MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL CANCER CACHEXIA MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CANCER CACHEXIA MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL CANCER CACHEXIA MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CANCER CACHEXIA MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS CANCER CACHEXIA MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA CANCER CACHEXIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA CANCER CACHEXIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA CANCER CACHEXIA MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE CANCER CACHEXIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST CANCER CACHEXIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA CANCER CACHEXIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC CANCER CACHEXIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL CANCER CACHEXIA MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN CANCER CACHEXIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC CANCER CACHEXIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION CANCER CACHEXIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS CANCER CACHEXIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 CANCER CACHEXIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO CANCER CACHEXIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL CANCER CACHEXIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. CANCER CACHEXIA MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. CANCER CACHEXIA MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CANCER CACHEXIA MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CANCER CACHEXIA MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL CANCER CACHEXIA MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL CANCER CACHEXIA MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL CANCER CACHEXIA MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL CANCER CACHEXIA MARKET SIZE, BY MEDICAL DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL CANCER CACHEXIA MARKET SIZE, BY MEDICAL DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL CANCER CACHEXIA MARKET SIZE, BY MEDICAL DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL CANCER CACHEXIA MARKET SIZE, BY MEDICAL DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL CANCER CACHEXIA MARKET SIZE, BY MEDICAL DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL CANCER CACHEXIA MARKET SIZE, BY MEDICAL DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL CANCER CACHEXIA MARKET SIZE, BY NUTRACEUTICALS & SUPPLEMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL CANCER CACHEXIA MARKET SIZE, BY NUTRACEUTICALS & SUPPLEMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL CANCER CACHEXIA MARKET SIZE, BY NUTRACEUTICALS & SUPPLEMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL CANCER CACHEXIA MARKET SIZE, BY NUTRACEUTICALS & SUPPLEMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL CANCER CACHEXIA MARKET SIZE, BY NUTRACEUTICALS & SUPPLEMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL CANCER CACHEXIA MARKET SIZE, BY NUTRACEUTICALS & SUPPLEMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL CANCER CACHEXIA MARKET SIZE, BY PHARMACEUTICAL, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL CANCER CACHEXIA MARKET SIZE, BY PHARMACEUTICAL, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL CANCER CACHEXIA MARKET SIZE, BY PHARMACEUTICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL CANCER CACHEXIA MARKET SIZE, BY PHARMACEUTICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL CANCER CACHEXIA MARKET SIZE, BY PHARMACEUTICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL CANCER CACHEXIA MARKET SIZE, BY PHARMACEUTICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL CANCER CACHEXIA MARKET SIZE, BY PHARMACEUTICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL CANCER CACHEXIA MARKET SIZE, BY PHARMACEUTICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL CANCER CACHEXIA MARKET SIZE, BY ANAMORELIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL CANCER CACHEXIA MARKET SIZE, BY ANAMORELIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL CANCER CACHEXIA MARKET SIZE, BY ANAMORELIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL CANCER CACHEXIA MARKET SIZE, BY ANAMORELIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL CANCER CACHEXIA MARKET SIZE, BY ANAMORELIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL CANCER CACHEXIA MARKET SIZE, BY ANAMORELIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL CANCER CACHEXIA MARKET SIZE, BY APPETITE STIMULANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL CANCER CACHEXIA MARKET SIZE, BY APPETITE STIMULANTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL CANCER CACHEXIA MARKET SIZE, BY APPETITE STIMULANTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL CANCER CACHEXIA MARKET SIZE, BY APPETITE STIMULANTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL CANCER CACHEXIA MARKET SIZE, BY APPETITE STIMULANTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL CANCER CACHEXIA MARKET SIZE, BY APPETITE STIMULANTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL CANCER CACHEXIA MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL CANCER CACHEXIA MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL CANCER CACHEXIA MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL CANCER CACHEXIA MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL CANCER CACHEXIA MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL CANCER CACHEXIA MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL CANCER CACHEXIA MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL CANCER CACHEXIA MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL CANCER CACHEXIA MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL CANCER CACHEXIA MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL CANCER CACHEXIA MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL CANCER CACHEXIA MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL CANCER CACHEXIA MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL CANCER CACHEXIA MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL CANCER CACHEXIA MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL CANCER CACHEXIA MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL CANCER CACHEXIA MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL CANCER CACHEXIA MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL CANCER CACHEXIA MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL CANCER CACHEXIA MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL CANCER CACHEXIA MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL CANCER CACHEXIA MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL CANCER CACHEXIA MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL CANCER CACHEXIA MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL CANCER CACHEXIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL CANCER CACHEXIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL CANCER CACHEXIA MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL CANCER CACHEXIA MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL CANCER CACHEXIA MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL CANCER CACHEXIA MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL CANCER CACHEXIA MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL CANCER CACHEXIA MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL CANCER CACHEXIA MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL CANCER CACHEXIA MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL CANCER CACHEXIA MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL CANCER CACHEXIA MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL CANCER CACHEXIA MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL CANCER CACHEXIA MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL CANCER CACHEXIA MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL CANCER CACHEXIA MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL CANCER CACHEXIA MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL CANCER CACHEXIA MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL CANCER CACHEXIA MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL CANCER CACHEXIA MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL CANCER CACHEXIA MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL CANCER CACHEXIA MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL CANCER CACHEXIA MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL CANCER CACHEXIA MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL CANCER CACHEXIA MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL CANCER CACHEXIA MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL CANCER CACHEXIA MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL CANCER CACHEXIA MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL CANCER CACHEXIA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL CANCER CACHEXIA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL CANCER CACHEXIA MARKET SIZE, BY AMBULATORY CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL CANCER CACHEXIA MARKET SIZE, BY AMBULATORY CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL CANCER CACHEXIA MARKET SIZE, BY AMBULATORY CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL CANCER CACHEXIA MARKET SIZE, BY AMBULATORY CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL CANCER CACHEXIA MARKET SIZE, BY AMBULATORY CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL CANCER CACHEXIA MARKET SIZE, BY AMBULATORY CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL CANCER CACHEXIA MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL CANCER CACHEXIA MARKET SIZE, BY HOME CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL CANCER CACHEXIA MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL CANCER CACHEXIA MARKET SIZE, BY HOME CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL CANCER CACHEXIA MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL CANCER CACHEXIA MARKET SIZE, BY HOME CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL CANCER CACHEXIA MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL CANCER CACHEXIA MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL CANCER CACHEXIA MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL CANCER CACHEXIA MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL CANCER CACHEXIA MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL CANCER CACHEXIA MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL CANCER CACHEXIA MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL CANCER CACHEXIA MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL CANCER CACHEXIA MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL CANCER CACHEXIA MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL CANCER CACHEXIA MARKET SIZE, BY AGE GROUP, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL CANCER CACHEXIA MARKET SIZE, BY AGE GROUP, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL CANCER CACHEXIA MARKET SIZE, BY AGE GROUP, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL CANCER CACHEXIA MARKET SIZE, BY AGE GROUP, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL CANCER CACHEXIA MARKET SIZE, BY AGE GROUP, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL CANCER CACHEXIA MARKET SIZE, BY AGE GROUP, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL CANCER CACHEXIA MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL CANCER CACHEXIA MARKET SIZE, BY ADULT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL CANCER CACHEXIA MARKET SIZE, BY ADULT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL CANCER CACHEXIA MARKET SIZE, BY ADULT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL CANCER CACHEXIA MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL CANCER CACHEXIA MARKET SIZE, BY ADULT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL CANCER CACHEXIA MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL CANCER CACHEXIA MARKET SIZE, BY GERIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL CANCER CACHEXIA MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL CANCER CACHEXIA MARKET SIZE, BY GERIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL CANCER CACHEXIA MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL CANCER CACHEXIA MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL CANCER CACHEXIA MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL CANCER CACHEXIA MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL CANCER CACHEXIA MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL CANCER CACHEXIA MARKET SIZE, BY PEDIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL CANCER CACHEXIA MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL CANCER CACHEXIA MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL CANCER CACHEXIA MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL CANCER CACHEXIA MARKET SIZE, BY GENDER, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL CANCER CACHEXIA MARKET SIZE, BY GENDER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL CANCER CACHEXIA MARKET SIZE, BY GENDER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL CANCER CACHEXIA MARKET SIZE, BY GENDER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL CANCER CACHEXIA MARKET SIZE, BY GENDER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL CANCER CACHEXIA MARKET SIZE, BY GENDER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL CANCER CACHEXIA MARKET SIZE, BY GENDER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL CANCER CACHEXIA MARKET SIZE, BY FEMALE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL CANCER CACHEXIA MARKET SIZE, BY FEMALE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL CANCER CACHEXIA MARKET SIZE, BY FEMALE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL CANCER CACHEXIA MARKET SIZE, BY FEMALE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL CANCER CACHEXIA MARKET SIZE, BY FEMALE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL CANCER CACHEXIA MARKET SIZE, BY FEMALE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL CANCER CACHEXIA MARKET SIZE, BY MALE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL CANCER CACHEXIA MARKET SIZE, BY MALE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL CANCER CACHEXIA MARKET SIZE, BY MALE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL CANCER CACHEXIA MARKET SIZE, BY MALE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL CANCER CACHEXIA MARKET SIZE, BY MALE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL CANCER CACHEXIA MARKET SIZE, BY MALE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL CANCER CACHEXIA MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL CANCER CACHEXIA MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. AMERICAS CANCER CACHEXIA MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 164. AMERICAS CANCER CACHEXIA MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 165. AMERICAS CANCER CACHEXIA MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 166. AMERICAS CANCER CACHEXIA MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 167. AMERICAS CANCER CACHEXIA MARKET SIZE, BY PHARMACEUTICAL, 2018-2024 (USD MILLION)
  • TABLE 168. AMERICAS CANCER CACHEXIA MARKET SIZE, BY PHARMACEUTICAL, 2025-2032 (USD MILLION)
  • TABLE 169. AMERICAS CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 170. AMERICAS CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 171. AMERICAS CANCER CACHEXIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 172. AMERICAS CANCER CACHEXIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 173. AMERICAS CANCER CACHEXIA MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 174. AMERICAS CANCER CACHEXIA MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 175. AMERICAS CANCER CACHEXIA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 176. AMERICAS CANCER CACHEXIA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 177. AMERICAS CANCER CACHEXIA MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
  • TABLE 178. AMERICAS CANCER CACHEXIA MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2032 (USD MILLION)
  • TABLE 179. AMERICAS CANCER CACHEXIA MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. AMERICAS CANCER CACHEXIA MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. AMERICAS CANCER CACHEXIA MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
  • TABLE 182. AMERICAS CANCER CACHEXIA MARKET SIZE, BY GENDER, 2025-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA CANCER CACHEXIA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. NORTH AMERICA CANCER CACHEXIA MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA CANCER CACHEXIA MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 186. NORTH AMERICA CANCER CACHEXIA MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA CANCER CACHEXIA MARKET SIZE, BY PHARMACEUTICAL, 2018-2024 (USD MILLION)
  • TABLE 188. NORTH AMERICA CANCER CACHEXIA MARKET SIZE, BY PHARMACEUTICAL, 2025-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 190. NORTH AMERICA CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA CANCER CACHEXIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 192. NORTH AMERICA CANCER CACHEXIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA CANCER CACHEXIA MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 194. NORTH AMERICA CANCER CACHEXIA MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA CANCER CACHEXIA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 196. NORTH AMERICA CANCER CACHEXIA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 197. NORTH AMERICA CANCER CACHEXIA MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
  • TABLE 198. NORTH AMERICA CANCER CACHEXIA MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA CANCER CACHEXIA MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. NORTH AMERICA CANCER CACHEXIA MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA CANCER CACHEXIA MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
  • TABLE 202. NORTH AMERICA CANCER CACHEXIA MARKET SIZE, BY GENDER, 2025-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA CANCER CACHEXIA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. LATIN AMERICA CANCER CACHEXIA MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA CANCER CACHEXIA MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 206. LATIN AMERICA CANCER CACHEXIA MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 207. LATIN AMERICA CANCER CACHEXIA MARKET SIZE, BY PHARMACEUTICAL, 2018-2024 (USD MILLION)
  • TABLE 208. LATIN AMERICA CANCER CACHEXIA MARKET SIZE, BY PHARMACEUTICAL, 2025-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 210. LATIN AMERICA CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 211. LATIN AMERICA CANCER CACHEXIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 212. LATIN AMERICA CANCER CACHEXIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 213. LATIN AMERICA CANCER CACHEXIA MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 214. LATIN AMERICA CANCER CACHEXIA MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA CANCER CACHEXIA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 216. LATIN AMERICA CANCER CACHEXIA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 217. LATIN AMERICA CANCER CACHEXIA MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
  • TABLE 218. LATIN AMERICA CANCER CACHEXIA MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2032 (USD MILLION)
  • TABLE 219. LATIN AMERICA CANCER CACHEXIA MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. LATIN AMERICA CANCER CACHEXIA MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. LATIN AMERICA CANCER CACHEXIA MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
  • TABLE 222. LATIN AMERICA CANCER CACHEXIA MARKET SIZE, BY GENDER, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA CANCER CACHEXIA MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA CANCER CACHEXIA MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA CANCER CACHEXIA MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA CANCER CACHEXIA MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA CANCER CACHEXIA MARKET SIZE, BY PHARMACEUTICAL, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE, MIDDLE EAST & AFRICA CANCER CACHEXIA MARKET SIZE, BY PHARMACEUTICAL, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE, MIDDLE EAST & AFRICA CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE, MIDDLE EAST & AFRICA CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE, MIDDLE EAST & AFRICA CANCER CACHEXIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE, MIDDLE EAST & AFRICA CANCER CACHEXIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPE, MIDDLE EAST & AFRICA CANCER CACHEXIA MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA CANCER CACHEXIA MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA CANCER CACHEXIA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA CANCER CACHEXIA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA CANCER CACHEXIA MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE, MIDDLE EAST & AFRICA CANCER CACHEXIA MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2032 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA CANCER CACHEXIA MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. EUROPE, MIDDLE EAST & AFRICA CANCER CACHEXIA MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA CANCER CACHEXIA MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA CANCER CACHEXIA MARKET SIZE, BY GENDER, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPE CANCER CACHEXIA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE CANCER CACHEXIA MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPE CANCER CACHEXIA MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPE CANCER CACHEXIA MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPE CANCER CACHEXIA MARKET SIZE, BY PHARMACEUTICAL, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE CANCER CACHEXIA MARKET SIZE, BY PHARMACEUTICAL, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPE CANCER CACHEXIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE CANCER CACHEXIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPE CANCER CACHEXIA MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE CANCER CACHEXIA MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE CANCER CACHEXIA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE CANCER CACHEXIA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE CANCER CACHEXIA MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE CANCER CACHEXIA MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE CANCER CACHEXIA MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE CANCER CACHEXIA MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE CANCER CACHEXIA MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE CANCER CACHEXIA MARKET SIZE, BY GENDER, 2025-2032 (USD MILLION)
  • TABLE 263. MIDDLE EAST CANCER CACHEXIA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. MIDDLE EAST CANCER CACHEXIA MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 265. MIDDLE EAST CANCER CACHEXIA MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 266. MIDDLE EAST CANCER CACHEXIA MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 267. MIDDLE EAST CANCER CACHEXIA MARKET SIZE, BY PHARMACEUTICAL, 2018-2024 (USD MILLION)
  • TABLE 268. MIDDLE EAST CANCER CACHEXIA MARKET SIZE, BY PHARMACEUTICAL, 2025-2032 (USD MILLION)
  • TABLE 269. MIDDLE EAST CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 270. MIDDLE EAST CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 271. MIDDLE EAST CANCER CACHEXIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 272. MIDDLE EAST CANCER CACHEXIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 273. MIDDLE EAST CANCER CACHEXIA MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 274. MIDDLE EAST CANCER CACHEXIA MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 275. MIDDLE EAST CANCER CACHEXIA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 276. MIDDLE EAST CANCER CACHEXIA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 277. MIDDLE EAST CANCER CACHEXIA MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
  • TABLE 278. MIDDLE EAST CANCER CACHEXIA MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2032 (USD MILLION)
  • TABLE 279. MIDDLE EAST CANCER CACHEXIA MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 280. MIDDLE EAST CANCER CACHEXIA MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 281. MIDDLE EAST CANCER CACHEXIA MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
  • TABLE 282. MIDDLE EAST CANCER CACHEXIA MARKET SIZE, BY GENDER, 2025-2032 (USD MILLION)
  • TABLE 283. AFRICA CANCER CACHEXIA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 284. AFRICA CANCER CACHEXIA MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 285. AFRICA CANCER CACHEXIA MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 286. AFRICA CANCER CACHEXIA MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 287. AFRICA CANCER CACHEXIA MARKET SIZE, BY PHARMACEUTICAL, 2018-2024 (USD MILLION)
  • TABLE 288. AFRICA CANCER CACHEXIA MARKET SIZE, BY PHARMACEUTICAL, 2025-2032 (USD MILLION)
  • TABLE 289. AFRICA CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 290. AFRICA CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 291. AFRICA CANCER CACHEXIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 292. AFRICA CANCER CACHEXIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 293. AFRICA CANCER CACHEXIA MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 294. AFRICA CANCER CACHEXIA MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 295. AFRICA CANCER CACHEXIA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 296. AFRICA CANCER CACHEXIA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 297. AFRICA CANCER CACHEXIA MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
  • TABLE 298. AFRICA CANCER CACHEXIA MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2032 (USD MILLION)
  • TABLE 299. AFRICA CANCER CACHEXIA MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 300. AFRICA CANCER CACHEXIA MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 301. AFRICA CANCER CACHEXIA MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
  • TABLE 302. AFRICA CANCER CACHEXIA MARKET SIZE, BY GENDER, 2025-2032 (USD MILLION)
  • TABLE 303. ASIA-PACIFIC CANCER CACHEXIA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 304. ASIA-PACIFIC CANCER CACHEXIA MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 305. ASIA-PACIFIC CANCER CACHEXIA MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 306. ASIA-PACIFIC CANCER CACHEXIA MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 307. ASIA-PACIFIC CANCER CACHEXIA MARKET SIZE, BY PHARMACEUTICAL, 2018-2024 (USD MILLION)
  • TABLE 308. ASIA-PACIFIC CANCER CACHEXIA MARKET SIZE, BY PHARMACEUTICAL, 2025-2032 (USD MILLION)
  • TABLE 309. ASIA-PACIFIC CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 310. ASIA-PACIFIC CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 311. ASIA-PACIFIC CANCER CACHEXIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 312. ASIA-PACIFIC CANCER CACHEXIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 313. ASIA-PACIFIC CANCER CACHEXIA MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 314. ASIA-PACIFIC CANCER CACHEXIA MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 315. ASIA-PACIFIC CANCER CACHEXIA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 316. ASIA-PACIFIC CANCER CACHEXIA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 317. ASIA-PACIFIC CANCER CACHEXIA MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
  • TABLE 318. ASIA-PACIFIC CANCER CACHEXIA MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2032 (USD MILLION)
  • TABLE 319. ASIA-PACIFIC CANCER CACHEXIA MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 320. ASIA-PACIFIC CANCER CACHEXIA MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 321. ASIA-PACIFIC CANCER CACHEXIA MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
  • TABLE 322. ASIA-PACIFIC CANCER CACHEXIA MARKET SIZE, BY GENDER, 2025-2032 (USD MILLION)
  • TABLE 323. GLOBAL CANCER CACHEXIA MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 324. GLOBAL CANCER CACHEXIA MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 325. ASEAN CANCER CACHEXIA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 326. ASEAN CANCER CACHEXIA MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 327. ASEAN CANCER CACHEXIA MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 328. ASEAN CANCER CACHEXIA MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 329. ASEAN CANCER CACHEXIA MARKET SIZE, BY PHARMACEUTICAL, 2018-2024 (USD MILLION)
  • TABLE 330. ASEAN CANCER CACHEXIA MARKET SIZE, BY PHARMACEUTICAL, 2025-2032 (USD MILLION)
  • TABLE 331. ASEAN CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 332. ASEAN CANCER CACHEXIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 333. ASEAN CANCER CACHEXIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 334. ASEAN CANCER CACHEXIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 335. ASEAN CANCER CACHEXIA MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 336. ASEAN CANCER CACHEXIA MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 337. ASEAN CANCER CACHEXIA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 338. ASEAN CANCER CACHEXIA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 339. ASEAN CANCER CACHEXIA MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
  • TABLE 340. ASEAN CANCER CACHEXIA MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2032 (USD MILLION)
  • TABLE 341. ASEAN CANCER CACHEXIA MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 342. ASEAN CANCER CACHEXIA MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 343. ASEAN CANCER CACHEXIA MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
  • TABLE 344. ASEAN CANCER CACHEXIA MARKET SIZE, BY GENDER, 2025-2032 (USD MILLION)
  • TABLE 345. GCC CANCER CACHEXIA